Axxcess Wealth Management LLC Boosts Stake in Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Axxcess Wealth Management LLC raised its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 0.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 194,907 shares of the biopharmaceutical company’s stock after acquiring an additional 1,696 shares during the period. Axxcess Wealth Management LLC’s holdings in Pfizer were worth $5,171,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Flagship Wealth Advisors LLC bought a new position in shares of Pfizer in the 4th quarter worth $420,000. Horizon Kinetics Asset Management LLC raised its position in Pfizer by 7.3% during the fourth quarter. Horizon Kinetics Asset Management LLC now owns 100,703 shares of the biopharmaceutical company’s stock valued at $2,672,000 after purchasing an additional 6,888 shares in the last quarter. Curio Wealth LLC bought a new stake in Pfizer during the fourth quarter worth about $32,000. Pitti Group Wealth Management LLC bought a new position in shares of Pfizer during the 4th quarter valued at about $375,000. Finally, Cibc World Markets Corp raised its holdings in shares of Pfizer by 17.3% during the 4th quarter. Cibc World Markets Corp now owns 902,242 shares of the biopharmaceutical company’s stock valued at $23,936,000 after buying an additional 133,084 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent research reports. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Citigroup decreased their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Get Our Latest Stock Report on Pfizer

Pfizer Trading Up 1.0 %

NYSE:PFE opened at $26.31 on Wednesday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average price of $26.21 and a 200-day moving average price of $27.09. The stock has a market cap of $149.09 billion, a price-to-earnings ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the firm posted $0.10 EPS. The business’s revenue was up 24.7% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).